Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis

Blood Adv. 2022 Jun 14;6(11):3339-3342. doi: 10.1182/bloodadvances.2021006934.

Authors

Mengyang Di^{1

2}, Can Cui³, Shalin K Kothari¹, Amer M Zeidan^{1

2}, Nikolai A Podoltsev^{1

2}, Natalia Neparidze^{1

2}, Rory M Shallis^{1

2}, Rong Wang^{2

4}, Xiaomei Ma^{2

4}, Scott F Huntington^{1

2}

Affiliations

¹ Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
² Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT.
³ Department of Immunobiology, Yale University School of Medicine, New Haven, CT; and.
⁴ Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Agammaglobulinaemia Tyrosine Kinase
Humans
Lymphoma, Mantle-Cell* / drug therapy
Protein Kinase Inhibitors / adverse effects

Substances

Protein Kinase Inhibitors
Agammaglobulinaemia Tyrosine Kinase

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States